Scn2a-related Epilepsy

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2025-04-01
Clinical Trial Update: Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating a personalized antisense oligonucleotide therapy for SCN2A-related epilepsy in children; the study …